Most tumor specific antigens (TAA) represent proteins also expressed at some level by normal cells. Self-tolerance would necessarily prohibit responsiveness by the host to such TAA. This is a proposal to obtain CTL specific for TAA by allo or xeno-immunization with tumor cells. Recent studies have demonstrated that allospecific CTL recognize not just the allogeneic class I MHC molecule but also the myriad of endogenous peptides bound in the antigen binding groove of the class I molecule, including peptides that can serve as TAA. Therefore, by appropriate screening of allospecific clones, CTL specific for TAA can be found. To obtain CTL specific for TAA on human tumors we will use a recently constructed transgenic line that expresses human CD8 and responds as efficiently to HLA class I molecules as it does to mouse H-2. CTL specific for TAA will be used for tumor cell elimination in two complementary approaches. First, recognition by TAA specific CTL clones will be used as an assay in the purification of TAA peptides extracted directly from the groove of class I molecules. Such peptides will be sequenced and used to generate synthetic peptides that will serve as the basis for vaccine development and for immunotherapy. In a second approach, the genes encoding the variable regions of T cell receptors from TAA peptide specific CTL will be transferred into a retroviral vector that contains the sequences for human T cell receptor genes and used to transduce T cells derived from the tumor bearing host.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
AIDS and Related Research Study Section 4 (ARRD)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Scripps Research Institute
La Jolla
United States
Zip Code
Vosganian, Gregory S; Bos, Rinke; Sherman, Linda A (2012) Immunologic effects of an orally available BRAFV600E inhibitor in BRAF wild-type murine models. J Immunother 35:473-7
Bos, Rinke; Sherman, Linda A (2010) CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes. Cancer Res 70:8368-77
Wong, S B Justin; Bos, Rinke; Sherman, Linda A (2008) Tumor-specific CD4+ T cells render the tumor environment permissive for infiltration by low-avidity CD8+ T cells. J Immunol 180:3122-31
Verdeil, Gregory; Marquardt, Kristi; Surh, Charles D et al. (2008) Adjuvants targeting innate and adaptive immunity synergize to enhance tumor immunotherapy. Proc Natl Acad Sci U S A 105:16683-8
Lyman, Michael A; Nugent, C Thomas; Marquardt, Kristi L et al. (2005) The fate of low affinity tumor-specific CD8+ T cells in tumor-bearing mice. J Immunol 174:2563-72
Redmond, William L; Sherman, Linda A (2005) Peripheral tolerance of CD8 T lymphocytes. Immunity 22:275-84
Redmond, William L; Marincek, Boris C; Sherman, Linda A (2005) Distinct requirements for deletion versus anergy during CD8 T cell peripheral tolerance in vivo. J Immunol 174:2046-53
Lyman, Michael A; Aung, Sandra; Biggs, Judith A et al. (2004) A spontaneously arising pancreatic tumor does not promote the differentiation of naive CD8+ T lymphocytes into effector CTL. J Immunol 172:6558-67
Redmond, William L; Hernandez, Javier; Sherman, Linda A (2003) Deletion of naive CD8 T cells requires persistent antigen and is not programmed by an initial signal from the tolerogenic APC. J Immunol 171:6349-54
Kreuwel, Huub T C; Aung, Sandra; Silao, Cheryl et al. (2002) Memory CD8(+) T cells undergo peripheral tolerance. Immunity 17:73-81

Showing the most recent 10 out of 22 publications